Frequently Asked Questions

What Do I Need to Know About IV Vitamin Infusions?

Who can get an IV?

Typically, almost anyone. We only treat adults in our facility and require that patient be at least 18 years of age to receive therapy.

Your safety is our biggest concern and we do not treat patients with certain medical conditions such as heart failure, orarrhythmias, uncontrolled hypertension, chronic kidney disease and liver cirrhosis.

We will take your medical history prior to administering any treatments and make sure you are a good candidate for our specific therapies.

We do not administer IVs to pregnant women.

How does the IV work?

The benefits of IV therapy come from rapidly replacing fluids, electrolytes, medications and vitamins.

This is more rapid than ingesting the ingredients because you bypass the gastrointestinal tract and have a faster rate of absorption and faster effect of the vitamins.

What are the side effects of getting an IV? Are IVs safe?

Any time there is a needle physically entering the skin, there is a small risk of infection, bleeding, bruising and slight pain.

We do all we can to avoid these common side effects including proper prep, proper needle size and using trained professionals.

How long will it take?

Most infusions are completed within 35-45 minutes. Shots only take a few minutes.

Booking an appointment ahead of time will save you time in the clinic.

Do You Accept Insurance?

We don’t accept private insurances for office visits and nutrition coaching.

We DO accept insurance for necessary blood work.

Our Treatments at Vital Wellness clinic are generally far less expensive than most co-pays, especially if you have a deductible based insurance plan.

Consultation Fee $150/ Follow up $60.

We do accept FSA and HSA accounts for services.

We do not offer refunds.

What is Semaglutide and tirzepatide?

Semaglutide, a single glucagon-like peptide (GLP-1) medication, and Tirzepatide, a dual peptide medication targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, are both administered on a weekly basis to patients who meet specific criteria.

These medications assist in the regulation of blood glucose levels, enhance the sensation of fullness, and diminish appetite.

On average, patients may experience a weight loss ranging from 10% to 15%. 

The most frequently reported adverse effects include nausea, constipation, diarrhea, and gastroesophageal reflux.

Initiating weight loss treatments necessitates a consultation with a licensed medical provider, as well as appropriate laboratory testing.

Do I Need Libido Therapy?

It is estimated that 1 in 10 women suffer from low sexual drive. There are hormonal and non hormonal treatments available to help women regain the sexual desire.

Men experience a decline in testosterone levels starting around the age of 30. Erectile dysfunction affects 50% of men in their 50s.

Vital Wellness understands and offers treatments for male and female sexual health concerns.

Sexual health treatments and Hormone replacement therapy will require a consultation and lab testing.

 

Cancelation Policy

If you need to reschedule or cancel your appointment, please contact the clinic by calling or emailing 24 hours prior to your scheduled appointment.

Do You Accept Insurance?

We accept insurance for GLP-1 / GIP for patients that qualify

Do You Have Studies For GLP-1 / GIP?

  • Malhotra A. et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. NEJM. June 21, 2024
  • Pugliese G, et al. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? J Endocrinol Invest. 2023 Sep
  • Mehdi SF, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023 May
  • López-Ojeda W, Hurley RA. Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry. J Neuropsychiatry Clin Neurosci. 2024
  • Hankosky ER, et al. Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial. Diabetes Obes Metab. 2023 Dec